NSTK · 01.2026Independent supplement reference
NutriStack
Edition 1.0Updated July 13, 2026

Semaglutide

Prescription ·Exploratory record · not publication-reviewed ·Updated July 13, 2026

Semaglutide is an FDA-approved glucagon-like peptide-1 (GLP-1) receptor agonist peptide drug available only as prescription semaglutide products such as Ozempic, Wegovy, and Rybelsus. Approved labeling covers type 2 diabetes, cardiovascular risk reduction in specified high-risk populations, chronic weight management, and selected Wegovy use for noncirrhotic MASH with moderate to advanced fibrosis. This app treats compounded, salt-form, research-use, vial-based, or non-prescribed semaglutide products as unsupported.

Evidence tier
Strong
Indexed sources
18 2021–2026
Interactions
0
Category
Prescription
Read the sources → Compare profiles
Publication status

Exploratory record, not a reviewed medical publication.

See the editorial and medical-review policies for the publication gate.

This generated database record has not completed a claim-level review by a qualified human medical reviewer. Bibliography links and evidence labels are not approval. The page remains available for reference and is excluded from search indexing.

In short

What the research says.

A quick, data-only summary. The full evidence, dosing, and sources are below.

Semaglutide is an FDA-approved glucagon-like peptide-1 (GLP-1) receptor agonist peptide drug available only as prescription semaglutide products such as Ozempic, Wegovy, and Rybelsus. NutriStack rates the supporting evidence as strong. Common adult dosing is Product-specific titration only: Ozempic injection 0.25-2 mg weekly; Rybelsus 3-14 mg daily; Ozempic tablets 1.5-9 mg daily; Wegovy injection 0.25-2.4 mg weekly, with selected adult weight-management patients up to 7.2 mg weekly per label; Wegovy tablets 1.5-25 mg daily (as prescribed by your clinician), though a prescriber sets the actual dose. This profile indexes 18 sources.

What it's good for
  • Improves glycemic control in adults with type 2 diabetes when prescribed3,5
  • Supports clinically meaningful weight reduction for labeled obesity/overweight indications5,7
  • Reduces major adverse cardiovascular events in labeled high-risk populations6,4
  • Wegovy labeling includes use for noncirrhotic MASH with moderate to advanced fibrosis in adults10,9
  • Once-weekly injection or once-daily tablet options depending on the approved product5,6
What to watch for
  • Nausea, vomiting, diarrhea, constipation, abdominal pain, and decreased appetite
  • Dyspepsia, reflux symptoms, abdominal distension, belching, or bloating
  • Injection-site reactions with injectable products
  • Personal or family history of medullary thyroid carcinoma (MTC)9
  • Multiple endocrine neoplasia syndrome type 2 (MEN 2)3,18

The bottom line

Evidence rating strong. Most-documented uses: improves glycemic control in adults with type 2 diabetes when prescribed, supports clinically meaningful weight reduction for labeled obesity/overweight indications, reduces major adverse cardiovascular events in labeled high-risk populations. 18 sources indexed (2021–2026), with 0 interaction records on file.

The science

How it works, mechanistically.

Core mechanism

A modified GLP-1 analogue with 94% homology to native GLP-1 that binds to and activates the GLP-1 receptor. Albumin binding via a fatty acid side chain extends the half-life to approximately 1 week. Enhances glucose-dependent insulin secretion, suppresses inappropriately elevated glucagon, slows gastric emptying, and reduces appetite through central hypothalamic mechanisms. The combination of these effects produces substantial glucose lowering and weight loss.

Class
GLP-1 Receptor Agonist
Absorption
Best on an empty stomach
Dosing

Dosing & protocol.

Common range
Product-specific titration only: Ozempic injection 0.25-2 mg weekly; Rybelsus 3-14 mg daily; Ozempic tablets 1.5-9 mg daily; Wegovy injection 0.25-2.4 mg weekly, with selected adult weight-management patients up to 7.2 mg weekly per label; Wegovy tablets 1.5-25 mg daily (as prescribed by your clinician)
Recommended form
FDA-approved prescription semaglutide product selected by the prescriber (Ozempic injection/tablets, Rybelsus tablets, or Wegovy injection/tablets). Do not use compounded, research-use-only, salt-form, or unverified vial/syringe semaglutide.

Oral semaglutide tablets must be taken in the morning on an empty stomach with no more than 4 oz plain water; swallow whole and wait at least 30 minutes before food, beverages, supplements, or other oral medications. Injectable products can be administered without regard to meals. Semaglutide delays gastric emptying, so narrow-therapeutic-index oral medications may need additional clinical monitoring.13

Safety

Full safety detail.

Side effects

  • Nausea, vomiting, diarrhea, constipation, abdominal pain, and decreased appetite
  • Dyspepsia, reflux symptoms, abdominal distension, belching, or bloating
  • Injection-site reactions with injectable products
  • Hypoglycemia risk increases when combined with insulin or insulin secretagogues
  • Acute pancreatitis has been reported with GLP-1 receptor agonists
  • Acute gallbladder disease
  • Acute kidney injury due to volume depletion from severe gastrointestinal adverse reactions
  • Diabetic retinopathy complications in susceptible patients with type 2 diabetes
  • Serious hypersensitivity reactions including anaphylaxis or angioedema
  • Pulmonary aspiration during general anesthesia or deep sedation has been reported postmarketing

Contraindications

  • Personal or family history of medullary thyroid carcinoma (MTC)9
  • Multiple endocrine neoplasia syndrome type 2 (MEN 2)3,18
  • Prior serious hypersensitivity reaction to semaglutide or product excipients9,13
Sources

Sources, by evidence tier.

Numbered references. Citations throughout the page link here.

Meta-analyses & systematic reviews

5

Randomized controlled trials

3

Reference material

10
FAQ

Common questions.

Quick answers about Semaglutide, drawn from the data on this page.

What is Semaglutide?

Semaglutide is an FDA-approved glucagon-like peptide-1 (GLP-1) receptor agonist peptide drug available only as prescription semaglutide products such as Ozempic, Wegovy, and Rybelsus. Approved labeling covers type 2 diabetes, cardiovascular risk reduction in specified high-risk populations, chronic weight management, and selected Wegovy use for noncirrhotic MASH with moderate to advanced fibrosis. This app treats compounded, salt-form, research-use, vial-based, or non-prescribed semaglutide products as unsupported.

What is Semaglutide used for?

Commonly cited benefits of Semaglutide include: Improves glycemic control in adults with type 2 diabetes when prescribed; Supports clinically meaningful weight reduction for labeled obesity/overweight indications; Reduces major adverse cardiovascular events in labeled high-risk populations; Wegovy labeling includes use for noncirrhotic MASH with moderate to advanced fibrosis in adults; Once-weekly injection or once-daily tablet options depending on the approved product. NutriStack rates the overall evidence as strong.

What is a typical dose of Semaglutide?

A typical adult dose of Semaglutide is Product-specific titration only: Ozempic injection 0.25-2 mg weekly; Rybelsus 3-14 mg daily; Ozempic tablets 1.5-9 mg daily; Wegovy injection 0.25-2.4 mg weekly, with selected adult weight-management patients up to 7.2 mg weekly per label; Wegovy tablets 1.5-25 mg daily (as prescribed by your clinician). The commonly recommended form is FDA-approved prescription semaglutide product selected by the prescriber (Ozempic injection/tablets, Rybelsus tablets, or Wegovy injection/tablets). Do not use compounded, research-use-only, salt-form, or unverified vial/syringe semaglutide.. These are general ranges, not personalized advice; confirm the right dose with a clinician.

What are the side effects of Semaglutide?

Reported side effects include nausea, vomiting, diarrhea, constipation, abdominal pain, and decreased appetite, dyspepsia, reflux symptoms, abdominal distension, belching, or bloating, injection-site reactions with injectable products, hypoglycemia risk increases when combined with insulin or insulin secretagogues, acute pancreatitis has been reported with glp-1 receptor agonists, acute gallbladder disease. This is educational information; check with a healthcare professional before use.

How strong is the evidence for Semaglutide?

NutriStack rates this as Strong, meaning multiple high-quality meta-analyses or systematic reviews converge on the same finding. Full tier criteria are at https://nutristackapp.com/methodology/evidence-tiers.

Use this with your stack

Semaglutide in NutriStack.

Add it to your stack, see how it interacts with everything else you take, and get a Stack Score that updates the moment it does.

Download on the App Store → Read the methodology

NutriStack is an informational and organizational tool, not a medical service, and not a substitute for professional advice. Always consult a qualified healthcare professional before starting, stopping, or changing any supplement or medication.